I. Lascombe

发表

Gene transfer into subcultured endometrial cells using lipofection.

P. Mougin, I. Lascombe, C. Vuillermoz, 1996, BioTechniques.

The PPARβ agonist L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanism.

I. Lascombe, H. Bittard, E. Roche, 2014, Cellular signalling.

Molecular and nanoscale evaluation of N-cadherin expression in invasive bladder cancer cells under control conditions or GW501516 exposure

I. Lascombe, H. Bittard, C. Elie-Caille, 2020, Molecular and Cellular Biochemistry.

Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up

F. Kleinclauss, I. Lascombe, H. Bittard, 2018, BMC Cancer.

Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.

H. Wallerand, J. Thiery, F. Radvanyi, 2010, Urologic oncology.

Expression of E-Cadherin and α-, β-, γ-Catenins in Patients With Bladder Cancer Identification of γ-Catenin as a New Prognostic Marker of Neoplastic Progression in T1 Superficial Urothelial Tumors

I. Lascombe, F. Mauny, H. Bittard, 2006 .

Apoptotic effect of the selective PPARβ/δ agonist GW501516 in invasive bladder cancer cells

I. Lascombe, H. Bittard, A. Péchery, 2016, Tumor Biology.

The Antidiabetic Drug Ciglitazone Induces High Grade Bladder Cancer Cells Apoptosis through the Up-Regulation of TRAIL

I. Lascombe, Marie-Laure Plissonnier, H. Bittard, 2011, PloS one.

N-Cadherin as a Novel Prognostic Marker of Progression in Superficial Urothelial Tumors

H. Wallerand, I. Lascombe, H. Bittard, 2006, Clinical Cancer Research.

A‐FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells

I. Lascombe, Marie-Laure Plissonnier, H. Bittard, 2009, International journal of cancer.

Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells

I. Lascombe, J. Rommelaere, Marie-Laure Plissonnier, 2017, Oncotarget.

ERE environment- and cell type-specific transcriptional effects of estrogen in normal endometrial cells

A. Weisz, I. Lascombe, C. Vuillermoz, 1998, Molecular and Cellular Endocrinology.

Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer.

I. Lascombe, H. Bittard, S. Fauconnet, 2009, Oncology reports.

Differential Regulation of Vascular Endothelial Growth Factor Expression by Peroxisome Proliferator-activated Receptors in Bladder Cancer Cells*

W. Wahli, B. Desvergne, I. Lascombe, 2002, The Journal of Biological Chemistry.

Estrogenic activity assessment of environmental chemicals using in vitro assays: identification of two new estrogenic compounds.

W. Wahli, I. Lascombe, U. Rüegg, 2000, Environmental health perspectives.

The human papillomavirus type 18 E6 oncoprotein induces Vascular Endothelial Growth Factor 121 (VEGF121) transcription from the promoter through a p53-independent mechanism.

I. Lascombe, Marie-Laure Plissonnier, L. Bermont, 2007, Experimental cell research.

Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up

F. Kleinclauss, I. Lascombe, H. Bittard, 2018, BMC Cancer.

Comparison of the effects of epidermal growth factor and fetal calf serum in human endometrial carcinoma RL95-2 cells.

I. Lascombe, M. Jouvenot, L. Bermont, 1997, Anticancer research.

Molecular and nanoscale evaluation of N-cadherin expression in invasive bladder cancer cells under control conditions or GW501516 exposure

I. Lascombe, H. Bittard, A. Péchery, 2020, Molecular and Cellular Biochemistry.

Insights on distinct pathways of thiazolidinediones (PPARγ ligand)‐promoted apoptosis in TRAIL‐sensitive or ‐resistant malignant urothelial cells

I. Lascombe, H. Bittard, S. Fauconnet, 2010, International journal of cancer.

Concomitant decrease of E- and A-FABP expression predicts worse survival in urothelial bladder cancer patients

I. Lascombe, M. Algros, S. Fauconnet, 2024, Scientific reports.

GW501516-Mediated Targeting of Tetraspanin 15 Regulates ADAM10-Dependent N-Cadherin Cleavage in Invasive Bladder Cancer Cells

I. Lascombe, A. Péchery, S. Fauconnet, 2024, Cells.